Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world-Reference-Cited by-同舟云学术

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

Published:2019-07-01 Issue:4 Volume:34 Page:794-801
ISSN:1226-3303
Container-title:The Korean Journal of Internal Medicine
language:en
Short-container-title:Korean J Intern Med

Author:

Oh Jae Young,Kim Byung Seok,Lee Chang Hyeong,Song Jeong Eun,Lee Heon Ju,Park Jung Gil,Hwang Jae Seok,Chung Woo Jin,Jang Byoung Kuk,Kweon Young Oh,Tak Won Young,Park Soo Young,Jang Se Young,Suh Jeong Ill,Kwak Sang Gyu

Publisher

Korean Association of Internal Medicine

Link

http://kjim.org/upload/kjim-2017-368.pdf

Reference22 articles.

1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

3. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

4. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

5. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study;Cureus;2024-08-30

2. Opportunities and challenges for the application of artificial intelligence paradigms into the management of endemic viral infections: The example of Chronic Hepatitis C Virus;Reviews in Medical Virology;2024-02-02

3. Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study;Medicina;2023-08-08

4. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation;Expert Opinion on Pharmacotherapy;2022-11-17

5. Current therapeutics against HCV;VirusDisease;2021-06